A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.
Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI
COVID-19
Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.
Wines BD, Trist HM, Esparon S, Impey RE, Mackay GA, Andrews RK, Soares da Costa TP, Pietersz GA, Baker RI, Hogarth PM
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians.
Hensen L, Nguyen THO, Rowntree LC, Damelang T, Koutsakos M, Aban M, Hurt A, Harland KL, Auladell M, van de Sandt CE, Everitt A, Blacker C, Oyong DA, Loughland JR, Webb JR, Wines BD, Hogarth PM, Flanagan KL, Plebanski M, Wheatley A, Chung AW, Kent SJ, Miller A, Clemens EB, Doherty PC, Nelson J, Davies J, Tong SYC, Kedzierska K
Global Infectious Disease Threats
A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination.
Lemke MM, McLean MR, Lee CY, Lopez E, Bozich ER, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kratochvil S, Wines BD, Hogarth PM, Kent SJ, Chung AW, Arnold KB
Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.
Anand SP, Ding S, Tolbert WD, Prévost J, Richard J, Gil HM, Gendron-Lepage G, Cheung WF, Wang H, Pastora R, Saxena H, Wakarchuk W, Medjahed H, Wines BD, Hogarth M, Shaw GM, Martin MA, Burton DR, Hangartner L, Evans DT, Pazgier M, Cossar D, McLean MD, Finzi A
Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A.
Xu H, Locarnini S, Wong D, Hammond R, Colledge D, Soppe S, Huynh T, Shaw T, Thompson AJ, Revill PA, Hogarth PM, Wines BD, Walsh R, Warner N